Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Charles Zhu
LIFE
Charles Zhu
LifeSci Capital
Wall Street Analyst
★★☆☆☆
#1962
on 13Foresight · ranked by our own returns
50%
Success Rate
-2.1%
Average Return
13 of 26 calls profitable · -16.7% vs benchmark
📈 Across the calls we could measure, roughly 50% of Charles Zhu's ratings turned a profit when each position was held for 2 year — averaging -2.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

178 Buy 7 Hold 0 Sell
Charles's Stock Coverage 23 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 2-Yr Return
CNTX
Context Therapeutics
 Jun 15, 2026 BUY Strong Buy
+879.2% avg upside
12 analysts
$6.00
849.56% Upside
 ·
IDYA
IDEAYA Biosciences
 Jun 15, 2026 BUY Strong Buy
+55.3% avg upside
29 analysts
$62.00
98.59% Upside
 +3.4%
KURA
Kura Oncology
 Jun 15, 2026 BUY Strong Buy
+162.8% avg upside
26 analysts
$28.00
182.00% Upside
 +0.3%
NUVL
Nuvalent
 Jun 13, 2026 HOLD Buy
-0.3% avg upside
21 analysts
$124.00
0.53% Upside
 +0.0%
IMNM
Immunome
 Jun 11, 2026 BUY Strong Buy
+83.2% avg upside
16 analysts
$40.00
113.50% Upside
 +0.9%
RCUS
Arcus Biosciences
 Jun 06, 2026 BUY Strong Buy
+38.0% avg upside
20 analysts
$46.00
89.23% Upside
 +3.6%
RVMD
Revolution Medicines
 Jun 01, 2026 BUY Strong Buy
-12.2% avg upside
32 analysts
$263.00
61.27% Upside
 -3.6%
STRO
Sutro Biopharma
 May 30, 2026 BUY Strong Buy
+31.8% avg upside
20 analysts
$54.00
82.24% Upside
 +1.9%
TARA
Protara Therapeutics
 May 20, 2026 BUY Strong Buy
+1153.9% avg upside
21 analysts
$26.00
553.33% Upside
 -18.1%
MOLN
Molecular Partners
 May 16, 2026 BUY Strong Buy
+161.4% avg upside
7 analysts
$12.00
214.21% Upside
 +10.5%
ZYME
Zymeworks
 May 09, 2026 BUY Strong Buy
+40.3% avg upside
25 analysts
$34.00
46.89% Upside
 -6.4%
CMPX
Compass Therapeutics
 May 09, 2026 BUY Strong Buy
+372.3% avg upside
19 analysts
$6.00
196.95% Upside
 +1.0%
ADAG
Adagene
 May 02, 2026 BUY Strong Buy
+92.6% avg upside
8 analysts
$8.00
102.96% Upside
 -9.6%
CBIO
Crescent Biopharma
 Apr 30, 2026 BUY Strong Buy
+26.4% avg upside
17 analysts
$28.00
58.19% Upside
 ·
GYRE
Gyre Therapeutics
 Jun 18, 2025 BUY Strong Buy
+212.0% avg upside
15 analysts
$22.00
252.05% Upside
 -22.8%
TNGX
Tango Therapeutics
 May 24, 2024 BUY Strong Buy
+24.2% avg upside
14 analysts
$14.00
50.05% Downside
 +192.9%
MGNX
MacroGenics
 Jan 02, 2024 BUY Buy
+326.4% avg upside
25 analysts
$20.00
384.23% Upside
 -84.2%
COGT
Cogent Biosciences
 Jun 13, 2023 BUY Strong Buy
+7.4% avg upside
26 analysts
$26.00
24.77% Downside
 -44.9%
XNCR
Xencor
 May 09, 2023 BUY Strong Buy
+159.5% avg upside
27 analysts
$39.00
208.55% Upside
 -69.0%
TRAW
Traws Pharma
 Mar 17, 2023 BUY Buy
+3604.6% avg upside
10 analysts
$5.00
487.97% Upside
 -86.8%
NGNE
Neurogene
 Jan 03, 2023 HOLD Strong Buy
+55.9% avg upside
23 analysts
 — +130.0%
PMVP
PMV Pharmaceuticals
 Jan 03, 2023 BUY Strong Buy
+1207.4% avg upside
12 analysts
$20.00
1669.99% Upside
 -81.7%
TSE:MDNA
Medicenna Therapeutics Corp
 Nov 29, 2022 BUY Strong Buy
+1092.1% avg upside
9 analysts
$2.00
365.04% Upside
 ·
🔒 18 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Charles Zhu — Frequently Asked Questions
How accurate are Charles Zhu's stock ratings?
Based on the calls 13Foresight could measure, about 50% of Charles's ratings were profitable over a one-year hold, with an average return of -6.3% per rating, or -13.9% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Charles ranked on 13Foresight?
Charles Zhu is currently ranked #1962 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Charles cover?
Charles most recently has ratings on CNTX, IDYA, KURA, NUVL, IMNM, RCUS, RVMD, STRO, TARA, MOLN, ZYME, CMPX and 11 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.